Quantifying an amyloid β model for Alzheimer's disease

Affiliations

¹ Department of Psychiatry and the Behavioral Sciences, and Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA. lschneid@usc.edu

Comment

Lon S Schneider. Lancet Neurol. 2013 Apr.

. 2013 Apr;12(4):327-8.

doi: 10.1016/S1474-4422(13)70050-4. Epub 2013 Mar 8.

¹ Department of Psychiatry and the Behavioral Sciences, and Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA. lschneid@usc.edu

No abstract available

Comment on

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Villemagne VL, et al. Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8. Lancet Neurol. 2013. PMID: 23477989